BioSyent

BioSyent EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of BioSyent (RX.V) as of Oct 27, 2026 is 15.53. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 18.31 — a change of -15.16% (lower).

EV/EBITDA

15.53

YoY

-15.16%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of BioSyent is 2025 15.53 . EV/EBITDA (Enterprise Value to EBITDA) of BioSyent was 2024 18.31 . It decreases by -15.16% lower compared to the previous year.

The BioSyent EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
21.67 CAD
Jan 1, 2019
27.39 CAD
Jan 1, 2020
27.40 CAD
Jan 1, 2021
17.25 CAD
Jan 1, 2022
19.96 CAD
Jan 1, 2023
18.87 CAD
Jan 1, 2024
18.31 CAD
Jan 1, 2025
15.53 CAD
The BioSyent EV/EBITDA history
YEAREV/EBITDAYoY
15.53-15.16%
18.31-2.97%
18.87-5.50%
19.96+15.74%
17.25-37.05%
27.40+0.05%
27.39+26.39%
21.67-2.42%
22.21-19.09%
27.45-15.44%
32.46-16.97%
39.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

EV/EBITDA (Enterprise Value to EBITDA) of BioSyent is 15.53 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of BioSyent changed from 18.31 to 15.53, representing a -15.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) BioSyent since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s BioSyent with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioSyent

All Key Metrics — BioSyent